The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients.
Biomarker
COVID-19
Mortality
SARS-CoV-2
Troponin
Journal
Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
ISSN: 1879-1336
Titre abrégé: Cardiovasc Pathol
Pays: United States
ID NLM: 9212060
Informations de publication
Date de publication:
Historique:
received:
05
05
2021
revised:
02
07
2021
accepted:
27
07
2021
pubmed:
7
8
2021
medline:
8
10
2021
entrez:
6
8
2021
Statut:
ppublish
Résumé
The variability of coronavirus disease 2019 (COVID-19) illness severity has puzzled clinicians and has sparked efforts to better predict who would benefit from rapid intervention. One promising biomarker for in-hospital morbidity and mortality is cardiac troponin (cTn). A retrospective study of 1331 adult patients with COVID-19 admitted to the Rush University System in Illinois, USA was performed. Patients without cTn measurement during their admission or a history of end stage renal disease or stage 5 chronic kidney disease were excluded. Using logistic regression adjusted for baseline characteristics, pre-existing comorbidities, and other laboratory markers of inflammation, cTn was assessed as a predictor of 60-day mortality and severe COVID-19 infection, consisting of a composite of 60-day mortality, need for intensive care unit, or requiring non-invasive positive pressure ventilation or intubation. A total of 772 patients met inclusion criteria. Of these, 69 (8.9%) had mild cTn elevation (> 1 to < 2x upper limit of normal (ULN)) and 46 (6.0%) had severe cTn elevation (≥ 2x ULN). Regardless of baseline characteristics, comorbidities, and initial c-reactive protein, lactate dehydrogenase, and ferritin, when compared to the normal cTn group, mild cTn elevation and severe cTn elevation were predictors of severe COVID-19 infection (adjusted OR [aOR] aOR 3.00 [CI: 1.51 - 6.29], P < 0.01; aOR 9.96 [CI: 2.75 - 64.23], P < 0.01, respectively); severe cTn elevation was a predictor of in-hospital mortality (aOR 2.42 [CI: 1.10 - 5.21], P < 0.05) and 60-day mortality (aOR 2.45 [CI: 1.13 - 5.25], P < 0.05). In our cohort, both mild and severe initial cTn elevation were predictors of severe COVID-19 infection, while only severe cTn elevation was predictive of 60-day mortality. First cTn value on hospitalization is a valuable longitudinal prognosticator for COVID-19 disease severity and mortality.
Sections du résumé
BACKGROUND
BACKGROUND
The variability of coronavirus disease 2019 (COVID-19) illness severity has puzzled clinicians and has sparked efforts to better predict who would benefit from rapid intervention. One promising biomarker for in-hospital morbidity and mortality is cardiac troponin (cTn).
METHODS
METHODS
A retrospective study of 1331 adult patients with COVID-19 admitted to the Rush University System in Illinois, USA was performed. Patients without cTn measurement during their admission or a history of end stage renal disease or stage 5 chronic kidney disease were excluded. Using logistic regression adjusted for baseline characteristics, pre-existing comorbidities, and other laboratory markers of inflammation, cTn was assessed as a predictor of 60-day mortality and severe COVID-19 infection, consisting of a composite of 60-day mortality, need for intensive care unit, or requiring non-invasive positive pressure ventilation or intubation.
RESULTS
RESULTS
A total of 772 patients met inclusion criteria. Of these, 69 (8.9%) had mild cTn elevation (> 1 to < 2x upper limit of normal (ULN)) and 46 (6.0%) had severe cTn elevation (≥ 2x ULN). Regardless of baseline characteristics, comorbidities, and initial c-reactive protein, lactate dehydrogenase, and ferritin, when compared to the normal cTn group, mild cTn elevation and severe cTn elevation were predictors of severe COVID-19 infection (adjusted OR [aOR] aOR 3.00 [CI: 1.51 - 6.29], P < 0.01; aOR 9.96 [CI: 2.75 - 64.23], P < 0.01, respectively); severe cTn elevation was a predictor of in-hospital mortality (aOR 2.42 [CI: 1.10 - 5.21], P < 0.05) and 60-day mortality (aOR 2.45 [CI: 1.13 - 5.25], P < 0.05).
CONCLUSION
CONCLUSIONS
In our cohort, both mild and severe initial cTn elevation were predictors of severe COVID-19 infection, while only severe cTn elevation was predictive of 60-day mortality. First cTn value on hospitalization is a valuable longitudinal prognosticator for COVID-19 disease severity and mortality.
Identifiants
pubmed: 34358679
pii: S1054-8807(21)00058-2
doi: 10.1016/j.carpath.2021.107374
pmc: PMC8330143
pii:
doi:
Substances chimiques
Biomarkers
0
Troponin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107374Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Références
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Am J Cardiol. 2021 Jan 1;138:100-106
pubmed: 33058800
Hypertension. 2020 Oct;76(4):1104-1112
pubmed: 32673499
Mayo Clin Proc. 2021 Jan;96(1):183-202
pubmed: 33413817
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Life Sci. 2020 Aug 1;254:117788
pubmed: 32475810
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Biomark Res. 2020 Aug 31;8:37
pubmed: 32879731
Eur Heart J. 2020 Jun 7;41(22):2070-2079
pubmed: 32391877
JAMA Cardiol. 2020 Jul 1;5(7):819-824
pubmed: 32219357
Clin Cardiol. 2021 Feb;44(2):276-283
pubmed: 33382482
J Am Coll Cardiol. 2020 Aug 4;76(5):533-546
pubmed: 32517963
JACC Cardiovasc Imaging. 2020 Aug;13(8):1792-1808
pubmed: 32762885
Lancet. 2021 Jan 16;397(10270):173-175
pubmed: 33428868
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Res Sq. 2020 Jun 13;:
pubmed: 32702736
Int J Med Sci. 2021 Jan 1;18(1):270-275
pubmed: 33390795
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
BMJ Evid Based Med. 2021 Jun;26(3):107-108
pubmed: 32934000
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Circulation. 2020 Jul 7;142(1):68-78
pubmed: 32293910
JAMA. 2020 Oct 6;324(13):1317-1329
pubmed: 32876697
Am J Med. 2010 Nov;123(11):1049-58
pubmed: 21035593
Am J Cardiol. 2020 Nov 15;135:150-153
pubmed: 32861733
Clin Chem. 2012 Sep;58(9):1342-51
pubmed: 22791885
Cell. 2020 Jul 9;182(1):59-72.e15
pubmed: 32492406
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353
Crit Rev Clin Lab Sci. 2020 Sep;57(6):389-399
pubmed: 32503382